Printer Friendly

CANADIAN COMPANY AWARDED WORLD-WIDE MARKETING RIGHT FOR NEW ANTI-CAVITY DRUG

CANADIAN COMPANY AWARDED WORLD-WIDE MARKETING RIGHT FOR NEW ANTI-CAVITY
 DRUG
 TORONTO, Oct. 1 /CNW/ - On September 29, 1992, Mr. Ross Perry, President, Knowell Therapeutic Technologies Inc. announced that the company has signed a 14 year contract with Apotex Scientific Inc. (a member of the Apotex Healthcare Group) to market worldwide the new anti-caries drug, CHLORZOIN. Apotex will produce the drug for the world market at its Toronto manufacturing facility.
 The drug, which has received patents in 11 countries for its unique chemistry and product efficacy, is a two stage treatment applied by a dentist or hygienist. Extensive clinical research and human testing of Chlorzoin indicates a dramatic reduction in oral bacteria known as MUTANS STREPTOCOCCI - the bacteria responsible for between 90 and 95 per cent of all dental caries (cavities) in children and young adults.
 "What makes Chlorzoin different than any other therapeutic treatment for the prevention of cavities is its sustained release. A single, two stage topical treatment can control the cavity-causing bacteria for six months or more" said Perry. "The application only takes about 20 minutes, involves no pain, and has not produced any side-effects whatsoever" added Perry.
 In a related five year study it was found that reducing mutans streptococci in parents decreased both the bacteria count in their children (transmitted from their parents) and the incidence of cavities. This suggests that reduction of the bacteria in parents, in particular mothers, may also be a preventive measure in the control of cavities in children.
 Chlorzoin was developed in the mid-80's by the Faculty of Dentistry, University of Toronto, led by the Head of Microbiology, Dr. James Sandham, DDS, PhD. Dr. Sandham has published several papers on preventive dentistry and is internationally recognized as an authority in this area.
 For their work on Chlorzoin, the University of Toronto Innovations Foundation was awarded the prestigious Award For Business Excellence by the Government of Canada in 1988 and has received extensive financial and technical support from the Medical Research Council of Canada.
 Knowell Therapeutic Technologies is applying for New Drug Status in several European countries and hopes to receive final approval from the Canadian regulatory authorities in early 1993 to market the drug in Canada. Following initial submissions to the United States Food and Drug Administration (FDA), Knowell expects to obtain approval in that country in 1994/95.
 The drug is designed to be administered at the time of routine professional dental cleaning and is expected to be at an equivalent cost to the patient.
 For further information: Ross Perry, Knowell Therapeutic Technologies Inc., 298 Kennedy Ave., Toronto, Ontario, M6P 3C3, (416) 762-8051, Fax: (416) 762-0128
 -0- 10/01/92


CO: KNOWELL THERAPEUTIC TECHNOLOGIES INC.; APOTEX
 SCIENTIFIC INC.


IN: MTC SU: PDT ST: -- c0083 -- X024 10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:458
Previous Article:SCOTIABANK INCREASES GUARANTEED INVESTMENT CERTIFICATE (GIC) RATES
Next Article:NEWTEL ENTERPRISES LIMITED
Topics:


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES FOUR PRESCRIPTION PRODUCTS FROM SEARLE CANADA INC.
AGOURON-JT ALLIANCE EXPANDS INTO ANTI-VIRAL DRUGS; JT DOUBLES MAXIMUM R&D FUNDING TO $56 MILLION
Enamelon, Inc. Receives First Purchase Order from K-Mart
Practicing Poor Oral Hygiene Can Leave Kids and Parents Frowning When the Braces Come Off; Recent survey shows many parents unaware that children's...
74% of Parents Looking for Innovative Ways to Make the Oral Care Routine Fun for Kids; Just in Time for Back to School, Family Expert Donna Erickson...
CEL-SCI Receives Phase III Clinical Trial Go-Ahead for Cancer Drug.
Ranbaxy Launches In Canada.
GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.
Reportlinker Adds World Anti-Obesity Drugs Market Report.
US, UK and Canada anti-doping groups link info.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters